Literature DB >> 27542334

Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United States.

B J Metcalf1, S Chochua1, R E Gertz1, Z Li1, H Walker1, T Tran1, P A Hawkins1, A Glennen2, R Lynfield2, Y Li1, L McGee1, B Beall3.   

Abstract

Our whole genome sequence (WGS) pipeline was assessed for accurate prediction of antimicrobial phenotypes. For 2316 invasive pneumococcal isolates recovered during 2015 we compared WGS pipeline data to broth dilution testing (BDT) for 18 antimicrobials. For 11 antimicrobials categorical discrepancies were assigned when WGS-predicted MICs and BDT MICs predicted different categorizations for susceptibility, intermediate resistance or resistance, ranging from 0.9% (tetracycline) to 2.9% (amoxicillin). For β-lactam antibiotics, the occurrence of at least four-fold differences in MIC ranged from 0.2% (meropenem) to 1.0% (penicillin), although phenotypic retesting resolved 25%-78% of these discrepancies. Non-susceptibility to penicillin, predicted by penicillin-binding protein types, was 2.7% (non-meningitis criteria) and 23.8% (meningitis criteria). Other common resistance determinants included mef (475 isolates), ermB (191 isolates), ermB + mef (48 isolates), tetM (261 isolates) and cat (51 isolates). Additional accessory resistance genes (tetS, tet32, aphA-3, sat4) were rarely detected (one to three isolates). Rare core genome mutations conferring erythromycin-resistance included a two-codon rplD insertion (rplD69-KG-70) and the 23S rRNA A2061G substitution (six isolates). Intermediate cotrimoxazole-resistance was associated with one or two codon insertions within folP (238 isolates) or the folA I100L substitution (38 isolates), whereas full cotrimoxazole-resistance was attributed to alterations in both genes (172 isolates). The two levofloxacin-resistant isolates contained parC and/or gyrA mutations. Of 11 remaining isolates with moderately elevated MICs to both ciprofloxacin and levofloxacin, seven contained parC or gyrA mutations. The two rifampin-resistant isolates contained rpoB mutations. WGS-based antimicrobial phenotype prediction was an informative alternative to BDT for invasive pneumococci. Published by Elsevier Ltd.

Entities:  

Keywords:  Accessory genome; Core genome; Minimum inhibitory concentrations; Pneumococcal; Whole genome

Mesh:

Substances:

Year:  2016        PMID: 27542334     DOI: 10.1016/j.cmi.2016.08.001

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  49 in total

1.  Penicillin-Binding Protein Typing, Antibiotic Resistance Gene Identification, and Molecular Phylogenetic Analysis of Meropenem-Resistant Streptococcus pneumoniae Serotype 19A-CC3111 Strains in Japan.

Authors:  Satoshi Nakano; Takao Fujisawa; Yutaka Ito; Bin Chang; Yasufumi Matsumura; Masaki Yamamoto; Shigeru Suga; Makoto Ohnishi; Miki Nagao
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

2.  Whole-Genome Sequencing Analysis of Multidrug-Resistant Serotype 15A Streptococcus pneumoniae in Japan and the Emergence of a Highly Resistant Serotype 15A-ST9084 Clone.

Authors:  Satoshi Nakano; Takao Fujisawa; Yutaka Ito; Bin Chang; Yasufumi Matsumura; Masaki Yamamoto; Shigeru Suga; Makoto Ohnishi; Miki Nagao
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Using Machine Learning To Predict Antimicrobial MICs and Associated Genomic Features for Nontyphoidal Salmonella.

Authors:  Marcus Nguyen; S Wesley Long; Patrick F McDermott; Randall J Olsen; Robert Olson; Rick L Stevens; Gregory H Tyson; Shaohua Zhao; James J Davis
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

4.  WGS to predict antibiotic MICs for Neisseria gonorrhoeae.

Authors:  David W Eyre; Dilrini De Silva; Kevin Cole; Joanna Peters; Michelle J Cole; Yonatan H Grad; Walter Demczuk; Irene Martin; Michael R Mulvey; Derrick W Crook; A Sarah Walker; Tim E A Peto; John Paul
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

5.  Prolonged and large outbreak of invasive group A Streptococcus disease within a nursing home: repeated intrafacility transmission of a single strain.

Authors:  S A Nanduri; B J Metcalf; M A Arwady; C Edens; M A Lavin; J Morgan; W Clegg; A Beron; J P Albertson; R Link-Gelles; A Ogundimu; J Gold; D Jackson; S Chochua; N Stone; C Van Beneden; K Fleming-Dutra; B Beall
Journal:  Clin Microbiol Infect       Date:  2018-05-18       Impact factor: 8.067

Review 6.  Genomic sequencing of Neisseria gonorrhoeae to respond to the urgent threat of antimicrobial-resistant gonorrhea.

Authors:  A Jeanine Abrams; David L Trees
Journal:  Pathog Dis       Date:  2017-06-01       Impact factor: 3.166

7.  Gain- and Loss-of-Function Screens Coupled to Next-Generation Sequencing for Antibiotic Mode of Action and Resistance Studies in Streptococcus pneumoniae.

Authors:  Hélène Gingras; Kévin Patron; Arijit Bhattacharya; Philippe Leprohon; Marc Ouellette
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

8.  Pathogen Genomics in Public Health.

Authors:  Gregory L Armstrong; Duncan R MacCannell; Jill Taylor; Heather A Carleton; Elizabeth B Neuhaus; Richard S Bradbury; James E Posey; Marta Gwinn
Journal:  N Engl J Med       Date:  2019-12-26       Impact factor: 91.245

9.  Rapid Nanopore Sequencing of Plasmids and Resistance Gene Detection in Clinical Isolates.

Authors:  Jamie K Lemon; Pavel P Khil; Karen M Frank; John P Dekker
Journal:  J Clin Microbiol       Date:  2017-10-11       Impact factor: 5.948

10.  Upsurge of Conjugate Vaccine Serotype 4 Invasive Pneumococcal Disease Clusters Among Adults Experiencing Homelessness in California, Colorado, and New Mexico.

Authors:  Bernard Beall; Hollis Walker; Theresa Tran; Zhongya Li; Jasmine Varghese; Lesley McGee; Yuan Li; Benjamin J Metcalf; Ryan Gierke; Emily Mosites; Sopio Chochua; Tamara Pilishvili
Journal:  J Infect Dis       Date:  2021-04-08       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.